TY  - JOUR
TI  - Long-term proton pump inhibitor use is a risk factor for mortality in patients hospitalized for COVID-19
AB  - Background and aim: The aim of this study is to evaluate whether the long-term (≥4 weeks) use of proton pump inhibitors (PPIs) is a risk factor for intubation requirement and mortality in patients hospitalized for COVID-19. Materials and methods: In this multicentric retrospective study, a total of 382 adult patients (≥18 years of age) with confirmed COVID-19 who were hospitalized for treatment were enrolled. The patients were divided into two groups according to the periods during which they used PPIs: the first group included patients who were not on PPI treatment, and the second group included those who have used PPIs for more than 4 weeks. Results: The study participants were grouped according to their PPI usage history over the last 6 months. In total, 291 patients did not use any type of PPI over the last 6 months, and 91 patients used PPIs for more than 4 weeks. Older age (HR: 1.047, 95% CI: 1.026–1.068), current smoking (HR: 2.590, 95% CI: 1.334–5.025), and PPI therapy for more than 4 weeks (HR: 1.83, 95% CI: 1.06–2.41) were found to be independent risk factors for mortality. Conclusion: The results obtained in this study show that using PPIs for more than 4 weeks is associated with negative outcomes for patients with COVID-19. Patients receiving PPI therapy should be evaluated more carefully if they are hospitalized for COVID-19 treatment.Key words: Covid-19, proton pump inhibitors, mortality
AU  - Can, Güray
AU  - Gürler, Müjgan
AU  - kekilli, murat
AU  - YALÇIN, Kadir Serkan
AU  - Kara, Umut
AU  - Sakin, Yusuf Serdar
AU  - Tanoglu, Alpaslan
AU  - Kaban, Mehmet göktürk
AU  - kırsoy, mehmet
AU  - Yozgat, Ahmet
AU  - Kasapoglu, Benan
AU  - Kaplan, Mustafa
DO  - 10.3906/sag-2103-80
PY  - 2021
JO  - Turkish Journal of Medical Sciences
VL  - 51
IS  - 4
SN  - 1300-0144
SP  - 1675
EP  - 1681
DB  - TRDizin
UR  - http://search/yayin/detay/479976
ER  -